Optimal management of breast cancer in the elderly patient: current perspectives

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• FerlayJShinHRBrayFFormanDMathersCParkinDMEstimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Int J Cancer2010127122893291721351269
   PubMed Web of Science ®Google Scholar
• AdamiHOMalkerBHolmbergLPerssonIStoneBThe relation between survival and age at diagnosis in breast cancerN Engl J Med198631595595633736639
   PubMed Web of Science ®Google Scholar
• BastiaannetEPortieljeJEvan de VeldeCJLack of survival gain for elderly women with breast cancerOncologist201116441542321406470
   PubMed Web of Science ®Google Scholar
• BergmanLKluckHMvan LeeuwenFEThe influence of age on treatment choice and survival of elderly breast cancer patients in south-eastern Netherlands: a population-based studyEur J Cancer199228A8–9147514801515270
   PubMed Web of Science ®Google Scholar
• BotteriEBagnardiVGoldhirschAVialeGRotmenszNAxillary lymph node involvement in women with breast cancer: does it depend on age?Clin Breast Cancer201010431832120705566
   PubMed Web of Science ®Google Scholar
• GreerLTRosmanMCharles MylanderWA prediction model for the presence of axillary lymph node involvement in women with invasive breast cancer: a focus on older womenBreast J201420214715324475876
   PubMed Web of Science ®Google Scholar
• PiergaJYGirreVLaurenceVCharacteristics and outcome of 1,755 operable breast cancers in women over 70 years of ageBreast200413536937515454191
   PubMed Web of Science ®Google Scholar
• GennariRCuriglianoGRotmenszNBreast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patientsCancer200410161302131015316944
   PubMed Web of Science ®Google Scholar
• Laird-FickHSGardinerJCTokalaHPatelPWeiSDimitrovNVHER2 status in elderly women with breast cancerJ Geriatr Oncol20134436236724472480
   PubMed Web of Science ®Google Scholar
• DiabSGElledgeRMClarkGMTumor characteristics and clinical outcome of elderly women with breast cancerJ Natl Cancer Inst200092755055610749910
   PubMed Web of Science ®Google Scholar
• YancikRRiesLGYatesJWBreast cancer in aging women. A population-based study of contrasts in stage, surgery, and survivalCancer19896359769812914302
   PubMed Web of Science ®Google Scholar
• SinghRHellmanSHeimannRThe natural history of breast carcinoma in the elderly: implications for screening and treatmentCancer200410091807181315112260
   PubMed Web of Science ®Google Scholar
• WildiersHVan CalsterBvan de Poll-FranseLVRelationship between age and axillary lymph node involvement in women with breast cancerJ Clin Oncol200927182931293719451448
   PubMed Web of Science ®Google Scholar
• GiordanoSHHortobagyiGNKauSWTheriaultRLBondyMLBreast cancer treatment guidelines in older womenJ Clin Oncol200523478379115681522
   PubMed Web of Science ®Google Scholar
• BarthélémyPHeitzDMathelinCAdjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposalsCrit Rev Oncol Hematol201179219620420655243
   PubMed Web of Science ®Google Scholar
• VestalREAging and pharmacologyCancer1997807130213109317183
   PubMed Web of Science ®Google Scholar
• SkirvinJALichtmanSMPharmacokinetic considerations of oral chemotherapy in elderly patients with cancerDrugs Aging2002191254211929325
   PubMed Web of Science ®Google Scholar
• BrennerBMMeyerTWHostetterTHDietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal diseaseN Engl J Med1982307116526597050706
   PubMed Web of Science ®Google Scholar
• LichtmanSMWildiersHChatelutEInternational Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients – an analysis of the medical literatureJ Clin Oncol200725141832184317488981
   PubMed Web of Science ®Google Scholar
• PutsMTHardtJMonetteJGirreVSpringallEAlibhaiSMUse of geriatric assessment for older adults in the oncology setting: a systematic reviewJ Natl Cancer Inst2012104151133116322851269
   PubMedGoogle Scholar
• PutsMTSantosBHardtJAn update on a systematic review of the use of geriatric assessment for older adults in oncologyAnn Oncol201425230731524256847
   PubMed Web of Science ®Google Scholar
• RepettoLFratinoLAudisioRAComprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology StudyJ Clin Oncol200220249450211786579
   PubMed Web of Science ®Google Scholar
• CailletPCanoui-PoitrineFVouriotJComprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA studyJ Clin Oncol201129273636364221709194
   PubMed Web of Science ®Google Scholar
• Clough-GorrKMThwinSSStuckAESillimanRAExamining five-and ten-year survival in older women with breast cancer using cancer-specific geriatric assessmentEur J Cancer201248680581221741826
   PubMed Web of Science ®Google Scholar
• SatarianoWARaglandDRThe effect of comorbidity on 3-year survival of women with primary breast cancerAnn Intern Med199412021041108256968
   PubMed Web of Science ®Google Scholar
• Clough-GorrKMStuckAEThwinSSSillimanRAOlder breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-upJ Clin Oncol201028338038620008637
   PubMed Web of Science ®Google Scholar
• ExtermannMMeyerJMcGinnisMA comprehensive geriatric intervention detects multiple problems in older breast cancer patientsCrit Rev Oncol Hematol2004491697514734156
   PubMed Web of Science ®Google Scholar
• SternbergSAThe Vulnerable Elders Survey: a tool for identifying vulnerable older people in the communityJ Am Geriatr Soc200351113914012534867
   PubMed Web of Science ®Google Scholar
• SlaetsJVulnerability in the elderly: frailtyMed Clin North Am200690459360116843764
   PubMed Web of Science ®Google Scholar
• BelleraCARainfrayMMathoulin-PélissierSScreening older cancer patients: first evaluation of the G-8 geriatric screening toolAnn Oncol20122382166217222250183
   PubMed Web of Science ®Google Scholar
• OvercashJABecksteadJMoodyLExtermannMCobbSThe Abbreviated Comprehensive Geriatric Assessment (aCGA) for use in the older cancer patient as a prescreen: scoring and interpretationCrit Rev Oncol Hematol200659320521016904902
   PubMed Web of Science ®Google Scholar
• KenisCBronDLibertYRelevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric studyAnn Oncol20132451306131223293115
   PubMed Web of Science ®Google Scholar
• SoubeyranPBelleraCGoyardJValidation of the G8 screening tool in geriatric oncology: the ONCODAGE projectJ Clin Oncol201129Suppl Abstr 9001
   Google Scholar
• Molina-GarridoMJGuillen-PonceCComparison of two frailty screening tools in older women with early breast cancerCrit Rev Oncol Hematol2011791516420663685
   PubMed Web of Science ®Google Scholar
• MieogJSDvan der HageJAvan de VeldeCJPreoperative chemotherapy for women with operable breast cancerCochrane Database Syst Rev20072CD00500217443564
   PubMed Web of Science ®Google Scholar
• SemiglazovVFSemiglazovVVDashyanGAPhase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancerCancer2007110224425417538978
   PubMed Web of Science ®Google Scholar
• AlbaECalvoLAlbanellJChemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II studyAnn Oncol201223123069307422674146
   PubMed Web of Science ®Google Scholar
• Imperial Cancer Clinical Research UnitChemotherapy or letrozole before surgery in treating postmenopausal women with breast cancer that can be removed by surgery Available from: http://clinicaltrials.gov/show/NCT0963729Accessed August 15, 2014
   Google Scholar
• Darb-EsfahaniSLoiblSMüllerBMIdentification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapyBreast Cancer Res2009115R6919758440
   PubMed Web of Science ®Google Scholar
• SeoJHKimYHKimJSMeta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancerCancer Chemother Pharmacol200963226126618365197
   PubMed Web of Science ®Google Scholar
• DixonJMRenshawLMacaskillEJIncrease in response rate by prolonged treatment with neoadjuvant letrozoleBreast Cancer Res Treat2009113114515118264759
   PubMed Web of Science ®Google Scholar
• VanderhaegenJWildiersHChristiaensMRResponse to neoadjuvant chemotherapy in elderly patients with locally advanced breast cancerCancer Res20117124 Suppl Abstr nr P3-14-22
   Google Scholar
• MillerKDMcCaskill-StevensWSiskJCombination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology GroupJ Clin Oncol199917103033303710506597
   PubMed Web of Science ®Google Scholar
• RoccoNRispoliCPaganoGBreast cancer surgery in elderly patients: postoperative complications and survivalBMC Surg201313Suppl 2S2524267004
   PubMed Web of Science ®Google Scholar
• De GlasNAKiderlenMBastiaannetEPostoperative complications and survival of elderly breast cancer patients: a FOCUS study analysisBreast Cancer Res Treat2013138256156923446810
   PubMed Web of Science ®Google Scholar
• PreecePEWoodRAMackieCRCuschieriATamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot studyBr Med (J Clin Res Ed)19822846319869870
   PubMed Web of Science ®Google Scholar
• FentimanISvan ZijlJKarydasITreatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10850 comparing modified radical mastectomy with tumorectomy plus tamoxifenEur J Cancer200339330030812565981
   PubMed Web of Science ®Google Scholar
• FentimanISChristiaensMRParidaensRTreatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomyEur J Cancer200339330931612565982
   PubMed Web of Science ®Google Scholar
• HindDWyldLReedMWSurgery, with or without tamoxifen, vs tamoxifen alone for older women with operable breast cancer: Cochrane reviewBr J Cancer20079671025102917285133
   PubMed Web of Science ®Google Scholar
• NguyenOSiderisLDroletPSurgery should complement endocrine therapy for elderly postmenopausal women with hormone receptor-positive early-stage breast cancerInt J Surg Oncol2012201218057422970358
   PubMedGoogle Scholar
• FennessyMBatesTMacRaeKRileyDHoughtonJBaumMLate follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancerBr J Surg200491669970415164437
   PubMed Web of Science ®Google Scholar
• MustacchiGCeccheriniRMilaniSTamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trialAnn Oncol200314341442012598347
   PubMed Web of Science ®Google Scholar
• ChakrabartiJKennyFSSyedBMRobertsonJFBlameyRWCheungKLA randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer – final results at 20-year follow-upCrit Rev Oncol Hematol201178326026420447833
   PubMed Web of Science ®Google Scholar
• JohnstonSJKennyFSSyedBMA randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-upAnn Oncol20122392296230022357257
   PubMed Web of Science ®Google Scholar
• SweeneyCSchmitzKHLazovichDVirnigBAWallaceRBFolsomARFunctional limitations in elderly female cancer survivorsJ Natl Cancer Inst200698852152916622121
   PubMedGoogle Scholar
• FallowfieldLJHallAMaguireGPBaumMPsychological outcomes of different treatment policies in women with early breast cancer outside a clinical trialBMJ199030167525755802242455
   PubMed Web of Science ®Google Scholar
• SingletarySERadiofrequency ablation of breast cancerAm Surg2003691374012575778
   PubMed Web of Science ®Google Scholar
• InalAAkmanTYamanSIs lymph node ratio prognostic factor for survival in elderly patients with node positive breast cancer? The Anatolian Society of Medical OncologyAnn Ital Chir20138414314823698146
   PubMed Web of Science ®Google Scholar
• SoaresEWNagaiHMBredtLCda CunhaADJrAndradeRJSoaresGVMorbidity after conventional dissection of axillary lymph nodes in breast cancer patientsWorld J Surg Oncol2014126724670000
   PubMed Web of Science ®Google Scholar
• MartelliGMiceliRDaidoneMGAxillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-upAnn Surg Oncol201118112513320652755
   PubMed Web of Science ®Google Scholar
• RudenstamCMZahriehDForbesJFfor International Breast Cancer Study GroupRandomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93J Clin Oncol200624333734416344321
   PubMed Web of Science ®Google Scholar
• MartelliGBoracchiPDe PaloMA randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-upAnn Surg200524211615973094
   PubMed Web of Science ®Google Scholar
• KragDNAndersonSJJulianTBSentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialLancet Oncol2010111092793320863759
   PubMed Web of Science ®Google Scholar
• GalimbertiVColeBFZurridaSAxillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trialLancet Oncol201314429730523491275
   PubMed Web of Science ®Google Scholar
• GiulianoAEHuntKKBallmanKVAxillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trialJAMA2011305656957521304082
   PubMed Web of Science ®Google Scholar
• AgrestiRMartelliGSandriMAxillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98)Cancer2014120688589324323615
   PubMed Web of Science ®Google Scholar
• LymanGHTeminSEdgeSBSentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateJ Clin Oncol201432131365138324663048
   PubMed Web of Science ®Google Scholar
• StraverMEMeijnenPvan TienhovenGRole of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancerJ Clin Oncol201028573173720038733
   PubMed Web of Science ®Google Scholar
• AugustDAWilkinsEReaTBreast reconstruction in older womenSurgery199411566636688197555
   PubMed Web of Science ®Google Scholar
• LipaJEYoussefAAKuererHMRobbGLChangDWBreast reconstruction in older women: advantages of autogenous tissuePlast Reconstr Surg200311131110112112621181
   PubMed Web of Science ®Google Scholar
• BowmanCCLennoxPAClugstonPACourtemancheDJBreast reconstruction in older women: should age be an exclusion criterion?Plast Reconstr Surg20061181162216816669
   PubMed Web of Science ®Google Scholar
• GirottoJASchreiberJNahabedianMYBreast reconstruction in the elderly: preserving excellent quality of lifeAnn Plast Surg200350657257812783001
   PubMed Web of Science ®Google Scholar
• HughesKSSchnaperLABerryDLumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancerN Engl J Med20043511097197715342805
   PubMed Web of Science ®Google Scholar
• HughesKSSchnaperLABellonJRLumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343J Clin Oncol201331192382238723690420
   PubMed Web of Science ®Google Scholar
• Van de WaterWBastiaannetEScholtenANBreast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysisAnn Surg Oncol201421378624271158
   PubMed Web of Science ®Google Scholar
• ClarkeMCollinsRDarbySEffects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trialsLancet200536695032087210616360786
   PubMed Web of Science ®Google Scholar
• SmithBDGrossCPSmithGLGalushaDHBekelmanJEHafftyBGEffectiveness of radiation therapy for older women with early breast cancerJ Natl Cancer Inst2006981068169016705122
   PubMedGoogle Scholar
• FisherBDignamJBryantJFive versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumorsJ Natl Cancer Inst19968821152915428901851
   PubMedGoogle Scholar
• KunklerIHWilliamsLWJackWThe PRIME II trial: wide local excision and adjuvant hormonal therapy ± postoperative whole breast irradiation in women ≥65 years with early breast cancer managed by breast conservationAbstract S2-01 presented at the San Antonio Breast Cancer SymposiumSan Antonio, TX, USADecember 10–14, 2013
   Google Scholar
• LiviLPaiarFMeldolesiEThe management of elderly patients with T1–T2 breast cancer treated with or without radiotherapyEur J Surg Oncol200531547347815878258
   PubMed Web of Science ®Google Scholar
• FylesAWMcCreadyDRManchulLATamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancerN Engl J Med20043511096397015342804
   PubMed Web of Science ®Google Scholar
• TruongPTBernsteinVLesperanceMSpeersCHOlivottoIARadiotherapy omission after breast-conserving surgery is associated with reduced breast cancer-specific survival in elderly women with breast cancerAm J Surg2006191674975516720143
   PubMed Web of Science ®Google Scholar
• AlbertJMPanIWShihYCEffectiveness of radiation for prevention of mastectomy in older breast cancer patients treated with conservative surgeryCancer2012118194642465122890779
   PubMed Web of Science ®Google Scholar
• WilliamsLJKunklerIHKingCCJackWvan der PolMA randomised controlled trial of post-operative radiotherapy following breast-conserving surgery in a minimum-risk population. Quality of life at 5 years in the PRIME trialHealth Technol Assess20111512ixi15721366974
   PubMed Web of Science ®Google Scholar
• ScallietPGKirkoveCBreast cancer in elderly women: can radiotherapy be omitted?Eur J Cancer200743152264226917643291
   PubMed Web of Science ®Google Scholar
• AlbertJMLiuDDShenYNomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgeryJ Clin Oncol201230232837284322734034
   PubMed Web of Science ®Google Scholar
• BartelinkHHoriotJCPoortmansPMImpact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trialJ Clin Oncol200725223259326517577015
   PubMed Web of Science ®Google Scholar
• SmithBDHafftyBGHurriaAGalushaDHGrossCPPostmastectomy radiation and survival in older women with breast cancerJ Clin Oncol200624304901490717050874
   PubMed Web of Science ®Google Scholar
• KunklerIHCanneyPvan TienhovenGRussellNSMRC/EORTC (BIG 2-04) SUPREMO Trial Management GroupElucidating the role of chest wall irradiation in “intermediate-risk” breast cancer: the MRC/EORTC SUPREMO trialClin Oncol (R Coll Radiol)2008201313418345543
   PubMed Web of Science ®Google Scholar
• BiganzoliLWildiersHOakmanCManagement of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)Lancet Oncol2012134e148e16022469125
   PubMed Web of Science ®Google Scholar
• BentzenSMAgrawalRKAirdEGfor START Trialists’ GroupThe UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trialLancet200837196181098110718355913
   PubMed Web of Science ®Google Scholar
• HavilandJSOwenJRDewarJAThe UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trialsLancet Oncol201314111086109424055415
   PubMed Web of Science ®Google Scholar
• WhelanTJPignolJPLevineMNLong-term results of hypofractionated radiation therapy for breast cancerN Engl J Med2010362651352020147717
   PubMed Web of Science ®Google Scholar
• CourdiAOrtholanCHannoun-LéviJMLong-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patientsRadiother Oncol200679215616116698099
   PubMed Web of Science ®Google Scholar
• ValachisAMauriDPolyzosNPMavroudisDGeorgouliasVCasazzaGPartial breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized controlled trialsBreast J201016324525120210799
   PubMed Web of Science ®Google Scholar
• RibeiroGGMageeBSwindellRHarrisMBanerjeeSSThe Christie Hospital breast conservation trial: an update at 8 years from inceptionClin Oncol (R Coll Radiol)1993552782838305334
   PubMedGoogle Scholar
• DodwellDJDykerKBrownJA randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancerClin Oncol (R Coll Radiol)200517861862216372487
   PubMed Web of Science ®Google Scholar
• PolgárCFodorJMajorTBreast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma – 5-year results of a randomized trialInt J Radiat Oncol Biol Phys200769369470217531400
   PubMed Web of Science ®Google Scholar
• VaidyaJSJosephDJTobiasJSTargeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trialLancet201037697359110220570343
   PubMed Web of Science ®Google Scholar
• VaidyaJSWenzFBulsaraMRisk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trialLancet2014383991760361324224997
   PubMed Web of Science ®Google Scholar
• VeronesiUOrecchiaRMaisonneuvePIntraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trialLancet Oncol201314131269127724225155
   PubMed Web of Science ®Google Scholar
• ChristiansenPBjerreKEjlertsenBMortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in DenmarkJ Natl Cancer Inst2011103181363137221881042
   PubMedGoogle Scholar
• ThürlimannBKeshaviahACoatesASfor Breast International Group (BIG) 1-98 Collaborative GroupA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med2005353262747275716382061
   PubMed Web of Science ®Google Scholar
• ColleoniMGiobbie-HurderAReganMMAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyJ Clin Oncol20112991117112421321298
   PubMed Web of Science ®Google Scholar
• MussHBTuDIngleJNEfficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17J Clin Oncol200826121956196418332474
   PubMed Web of Science ®Google Scholar
• CrivellariDSunZCoatesASLetrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trialJ Clin Oncol200826121972197918332471
   PubMed Web of Science ®Google Scholar
• PhillipsKARibiKSunZCognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trialBreast201019538839520385495
   PubMed Web of Science ®Google Scholar
• SestakICuzickJSapunarFRisk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysisLancet Oncol20089986687218703382
   PubMed Web of Science ®Google Scholar
• KhanQJO’DeaAPSharmaPMusculoskeletal adverse events associated with adjuvant aromatase inhibitorsJ Oncol2010201065434820871846
   PubMedGoogle Scholar
• ZillerVKalderMAlbertUSAdherence to adjuvant endocrine therapy in postmenopausal women with breast cancerAnn Oncol200920343143619150950
   PubMed Web of Science ®Google Scholar
• Trial ID RECF2252 Available from: www.e-cancer.fr/recherche/recherche-clinique/registre-des-essais-cliniques. [French national clinical trials registry.]
   Google Scholar
• BeckerTLipscombeLNarodSSimmonsCAndersonGMRochonPASystematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancerJ Am Geriatr Soc20126091761176722985145
   PubMed Web of Science ®Google Scholar
• HadjiPAaproMSBodyJJManagement of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatmentAnn Oncol201122122546255521415233
   PubMed Web of Science ®Google Scholar
• FonteinDBSeynaeveCHadjiPSpecific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysisJ Clin Oncol201331182257226423610112
   PubMed Web of Science ®Google Scholar
• LeeSJLindquistKSegalMRCovinskyKEDevelopment and validation of a prognostic index for 4-year mortality in older adultsJAMA2006295780180816478903
   PubMed Web of Science ®Google Scholar
• CappellaniADi VitaMZanghìAPrognostic factors in elderly patients with breast cancerBMC Surg201313Suppl 2S224268048
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative GroupEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• RavdinPMSiminoffLADavisGJComputer program to assist in making decisions about adjuvant therapy for women with early breast cancerJ Clin Oncol200119498099111181660
   PubMed Web of Science ®Google Scholar
• HartmannSGerberBEllingDHeintzeKReimerTThe 70-gene signature as prognostic factor for elderly women with hormone receptor-positive, HER2-negative breast cancerBreast Care (Basel)201271192422553468
   PubMed Web of Science ®Google Scholar
• ChapmanJAMengDShepherdLCompeting causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancerJ Natl Cancer Inst2008100425226018270335
   PubMed Web of Science ®Google Scholar
• PetoRDaviesCGodwinJfor Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsLancet2012379981443244422152853
   PubMed Web of Science ®Google Scholar
• No authors listedPolychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative GroupLancet199835291329309429752815
   PubMed Web of Science ®Google Scholar
• MussHBBerryDACirrincioneCTAdjuvant chemotherapy in older women with early-stage breast cancerN Engl J Med2009360202055206519439741
   PubMed Web of Science ®Google Scholar
• MussHBBerryDACirrincioneCToxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B ExperienceJ Clin Oncol200725243699370417704418
   PubMed Web of Science ®Google Scholar
• LymanGHDaleDCWolffDAAcute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic reviewJ Clin Oncol201028172914292420385991
   PubMed Web of Science ®Google Scholar
• TannockIFAhlesTAGanzPAVan DamFSCognitive impairment associated with chemotherapy for cancer: report of a workshopJ Clin Oncol200422112233223915169812
   PubMed Web of Science ®Google Scholar
• SanoffHKDealAMKrishnamurthyJEffect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancerJ Natl Cancer Inst20141064dju05724681605
   PubMedGoogle Scholar
• CrivellariDBonettiMCastiglione-GertschMBurdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VIIJ Clin Oncol20001871412142210735888
   PubMed Web of Science ®Google Scholar
• De MaioEGravinaAPacilioCCompliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experienceBMC Cancer200553015790416
   PubMed Web of Science ®Google Scholar
• GiordanoSHDuanZKuoYFHortobagyiGNGoodwinJSUse and outcomes of adjuvant chemotherapy in older women with breast cancerJ Clin Oncol200624182750275616782915
   PubMed Web of Science ®Google Scholar
• ElkinEBHurriaAMitraNSchragDPanageasKSAdjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohortJ Clin Oncol200624182757276416782916
   PubMed Web of Science ®Google Scholar
• UNICANCERAdjuvant systemic treatment for (ER)-positive HER2-negative breast carcinoma in women over 70 according to genomic grade (GG): chemotherapy + endocrine treatment versus endocrine treatment (ASTER 70s) Available from: http://clinicaltrials.gov/show/NCT1564056Accessed August 15, 2014
   Google Scholar
• ExtermannMAlbrandGChenHAre older French patients as willing as older American patients to undertake chemotherapy?J Clin Oncol200321173214321912874269
   PubMed Web of Science ®Google Scholar
• MussHBWoolfSBerryDAdjuvant chemotherapy in older and younger women with lymph node-positive breast cancerJAMA200529391073108115741529
   PubMed Web of Science ®Google Scholar
• FargeotPBonneterreJRochéHDisease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trialJ Clin Oncol200422234622463015505276
   PubMed Web of Science ®Google Scholar
• PinderMCDuanZGoodwinJSHortobagyiGNGiordanoSHCongestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancerJ Clin Oncol200725253808381517664460
   PubMed Web of Science ®Google Scholar
• AaproMBernard-MartyCBrainEGAnthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paperAnn Oncol201122225726720956616
   PubMed Web of Science ®Google Scholar
• BrainEGMertensCGirreVImpact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trialCrit Rev Oncol Hematol201180116017021035352
   PubMed Web of Science ®Google Scholar
• FreyerGCamponeMPeronJAdjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational studyCrit Rev Oncol Hematol201180346647321565521
   PubMed Web of Science ®Google Scholar
• TakabatakeDTairaNHaraFFeasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patientsJpn J Clin Oncol200939847848319491086
   PubMed Web of Science ®Google Scholar
• JonesSHolmesFAO’ShaughnessyJDocetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735J Clin Oncol20092781177118319204201
   PubMed Web of Science ®Google Scholar
• SoongDHajRLeungMGHigh rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamideJ Clin Oncol20092726e101e10219652050
   PubMed Web of Science ®Google Scholar
• RomieuGClemensMMahlbergRPegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trialCrit Rev Oncol Hematol2007641647217317205
   PubMed Web of Science ®Google Scholar
• BalducciLAl-HalawaniHCharuVElderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastimOncologist200712121416142418165618
   PubMed Web of Science ®Google Scholar
• BrolloJCuriglianoGDisalvatoreDAdjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trialsCancer Treat Rev2013391445022541668
   PubMed Web of Science ®Google Scholar
• SawakiMTokudomeNMizunoTEvaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]Jpn J Clin Oncol201141570971221355003
   PubMed Web of Science ®Google Scholar
• BonneterreJBuzdarANabholtzJMAnastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer20019292247225811745278
   PubMed Web of Science ®Google Scholar
• NabholtzJMBonneterreJBuzdarARobertsonJFThürlimannBAnastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety resultsEur J Cancer200339121684168912888362
   PubMed Web of Science ®Google Scholar
• MouridsenHChaudri-RossHAEfficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancerOncologist20049549750615477634
   PubMed Web of Science ®Google Scholar
• MouridsenHGershanovichMSunYPhase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer GroupJ Clin Oncol200321112101210912775735
   PubMed Web of Science ®Google Scholar
• ParidaensRDirixLLohrischCMature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancerAnn Oncol20031491391139812954578
   PubMed Web of Science ®Google Scholar
• HowellAPippenJElledgeRMFulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trialsCancer2005104223623915937908
   PubMed Web of Science ®Google Scholar
• PritchardKIBurrisHA3rdItoYSafety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2Clin Breast Cancer2013136421432.e824267730
   PubMed Web of Science ®Google Scholar
• BottiniAGeneraliDBrizziMPRandomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patientsJ Clin Oncol200624223623362816877730
   PubMed Web of Science ®Google Scholar
• SwainSMWhaleyFSEwerMSCongestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trialsCancer200397112869287912767102
   PubMed Web of Science ®Google Scholar
• BiganzoliLColemanRMinisiniAA joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancerCrit Rev Oncol Hematol2007611848917116400
   PubMed Web of Science ®Google Scholar
• FalandryCBrainEBonnefoyMImpact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trialEur J Cancer201349132806281423735702
   PubMed Web of Science ®Google Scholar
• BassoURomaABrunelloABi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70 years)J Geriatr Oncol20134434034524472477
   PubMed Web of Science ®Google Scholar
• SmorenburgCHde GrootSMvan Leeuwen-StokAEA randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOGAnn Oncol201425359960524504445
   PubMed Web of Science ®Google Scholar
• BajettaEProcopioGCelioLSafety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older womenJ Clin Oncol200523102155216115710946
   PubMed Web of Science ®Google Scholar
• De SanctisRQuadriniSLongoFCapecitabine in elderly patients with metastatic breast cancerTumori201298330330722825504
   PubMed Web of Science ®Google Scholar
• SorioRRobieuxIGalligioniEPharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancerEur J Cancer19973323013039135505
   PubMed Web of Science ®Google Scholar
• AddeoRSgambatoACennamoGLow-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancerClin Breast Cancer201010430130620705563
   PubMed Web of Science ®Google Scholar
• Del MastroLPerroneFRepettoLWeekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)Ann Oncol200516225325815668279
   PubMed Web of Science ®Google Scholar
• Ten TijeAJSmorenburgCHSeynaeveCWeekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trialEur J Cancer200440335235714746852
   PubMed Web of Science ®Google Scholar
• LichtmanSMHurriaACirrincioneCTPaclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840Ann Oncol201223363263821693770
   PubMed Web of Science ®Google Scholar
• HainsworthJDBurrisHA3rdYardleyDAWeekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trialJ Clin Oncol200119153500350511481356
   PubMed Web of Science ®Google Scholar
• D’hondtRParidaensRWildiersHSafety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II studyAnticancer Drugs200415434134615057137
   PubMed Web of Science ®Google Scholar
• HurriaAFlemingMTBakerSDPharmacokinetics and toxicity of weekly docetaxel in older patientsClin Cancer Res20061220 Pt 16100610517062686
   PubMed Web of Science ®Google Scholar
• MussHCortesJVahdatLTEribulin monotherapy in patients aged 70 years and older with metastatic breast cancerOncologist201419431832724682463
   PubMed Web of Science ®Google Scholar
• DongNWangMLiHCuiYGuoQGemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancerCancer Chemother Pharmacol20126951315132222307763
   PubMed Web of Science ®Google Scholar
• RousseauFRetornazFJolyFImpact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: a multicentre pilot study of the French Geriatric Oncology Group (GERICO)Crit Rev Oncol Hematol2010761717820356760
   PubMed Web of Science ®Google Scholar
• EarleCCNevilleBALandrumMBAyanianJZBlockSDWeeksJCTrends in the aggressiveness of cancer care near the end of lifeJ Clin Oncol200422231532114722041
   PubMed Web of Science ®Google Scholar
• DufresneAPivotXTournigandCImpact of chemotherapy beyond the first line in patients with metastatic breast cancerBreast Cancer Res Treat2008107227527917380382
   PubMed Web of Science ®Google Scholar
• TsaiHTIsaacsCFuAZRisk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based studyBreast Cancer Res Treat2014144116317024469642
   PubMed Web of Science ®Google Scholar
• SerranoCCortésJDe Mattos-ArrudaLTrastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factorsAnn Oncol201223489790221828361
   PubMed Web of Science ®Google Scholar
• ZucchiniGBernardiAMartoniAZamagniCTolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancerAnn Oncol201324126426523251010
   PubMed Web of Science ®Google Scholar
• AdamoVRicciardiGRAdamoBThe risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer populationOncology2014861162124335608
   PubMed Web of Science ®Google Scholar
• BrunelloAMonfardiniSCrivellariDMulticenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (>70 years)J Clin Oncol200826Suppl Abstr 1096
   Google Scholar
• MilesDBaselgaJAmadoriDTreatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)Breast Cancer Res Treat20131421899924129974
   PubMed Web of Science ®Google Scholar
• KaufmanBMackeyJRClemensMRTrastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM studyJ Clin Oncol200927335529553719786670
   PubMed Web of Science ®Google Scholar
• JohnstonSPippenJJrPivotXLapatinib combined with letrozole versus letrozole and placebo as first-line therapy for post-menopausal hormone receptor-positive metastatic breast cancerJ Clin Oncol200927335538554619786658
   PubMed Web of Science ®Google Scholar
• RossariJRMetzger-FilhoOPaesmansMBevacizumab and breast cancer: a meta-analysis of first-line Phase III studies and a critical reappraisal of available evidenceJ Oncol2012201241767323008712
   PubMedGoogle Scholar
• PivotXSchneeweissAVermaSEfficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADOEur J Cancer201147162387239521757334
   PubMed Web of Science ®Google Scholar
• BiganzoliLCortes-FunesHThomssenCTolerability and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced breast cancer: subpopulation analysis of the MO 19391 studyJ Clin Oncol20092748 Suppl Abstr 1032
   Google Scholar
• GeberthMFoersterFKlarePEfficacy and safety of first-line bevacizumab combined with paclitaxel according to age: subpopulation analysis of a large, multicenter, non-interventional study in patients with HER2-negative metastatic breast cancerCancer Res20096924 Suppl Abstr nr 6085
   Web of Science ®Google Scholar
• SmithIEPiergaJYBiganzoliLFirst-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsAnn Oncol201122359560220819780
   PubMed Web of Science ®Google Scholar
• BiganzoliLDi VincenzoEJiangZFirst-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA studyAnn Oncol201223111111821444356
   PubMed Web of Science ®Google Scholar
• Aventis PharmaceuticalsWeekly docetaxel and CMF in the adjuvant treatment of elderly women with high-risk breast cancer Available from: http://clinicaltrials.gov/show/NCT0193011Accessed August 15, 2014
   Google Scholar
• Comprehensive Support Project for Oncology ResearchEvaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2 positive elderly breast cancer patients (RESPECT) Available from: http://clinicaltrials.gov/show/NCT1104935Accessed August 15, 2014
   Google Scholar
• European Organisation for Research and Treatment of CancerElderly metastatic breast cancer: pertuzumab-herceptin vs pertuzumab-herceptin-metronomic chemotherapy, followed by T-DM1 Available from: http://clinicaltrials.gov/show/NCT1597414Accessed August 15, 2014
   Google Scholar
• Danish Breast Cancer Cooperative GroupPartial breast versus whole breast irradiation in elderly women operated on for early breast cancer Available from: http://clinicaltrials.gov/show/NCT0892814Accessed August 15, 2014
   Google Scholar
• Regione Emilia-RomagnaBreast cancer with low risk of local recurrence: partial and accelerated radiation with three-dimensional conformal radiotherapy (3DCRT) vs standard radiotherapy after conserving surgery (Phase III Study) Available from: http://clinicaltrials.gov/show/NCT1803958Accessed August 15, 2014
   Google Scholar
• YellenSBCellaDFLeslieWTAge and clinical decision making in oncology patientsJ Natl Cancer Inst19948623176617707966414
   PubMedGoogle Scholar
• BouchardyCRapitiEFiorettaGUndertreatment strongly decreases prognosis of breast cancer in elderly womenJ Clin Oncol200321193580358712913099
   PubMed Web of Science ®Google Scholar
• BouchardyCRapitiEBlagojevicSVlastosATVlastosGOlder female cancer patients: importance, causes, and consequences of undertreatmentJ Clin Oncol200725141858186917488984
   PubMed Web of Science ®Google Scholar
• MlineritschBTauschCSingerCExemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)Breast Cancer Res Treat2008112120321318158620
   PubMed Web of Science ®Google Scholar
• Tubiana-HulinMBecetteVBiecheIExemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trialAnticancer Res2007274C2689269617695434
   PubMed Web of Science ®Google Scholar
• CataliottiLBuzdarAUNoguchiSComparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared with Tamoxifen (PROACT) trialCancer2006106102095210316598749
   PubMed Web of Science ®Google Scholar
• SmithIEDowsettMEbbsSRNeoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trialJ Clin Oncol200523225108511615998903
   PubMed Web of Science ®Google Scholar
• EiermannWPaepkeSAppfelstaedtJPreoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter studyAnn Oncol200112111527153211822750
   PubMed Web of Science ®Google Scholar
• GreenHStålOBachmeierKPegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identifiedCancer Lett2011313214515322056077
   PubMed Web of Science ®Google Scholar
• CrivellariDLombardiDCoronaGInnovative schedule of oral idarubicin in elderly patients with metastatic breast cancer: comprehensive results of a phase II multi-institutional study with pharmacokinetic drug monitoringAnn Oncol200617580781216497825
   PubMed Web of Science ®Google Scholar
• VogelCO’RourkeMWinerEVinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or olderAnn Oncol199910439740210370781
   PubMed Web of Science ®Google Scholar
• FeherOVodvarkaPJassemJFirst-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III studyAnn Oncol200516689990815821120
   PubMed Web of Science ®Google Scholar
• VahdatLTVrdoljakEGómezHEfficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline-and taxane-pretreated metastatic breast cancerJ Geriatr Oncol20134434635224472478
   PubMed Web of Science ®Google Scholar
• BeuselinckBWildiersHWynendaeleWDirixLKainsJPParidaensRWeekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical OncologyCrit Rev Oncol Hematol2010751707719651523
   PubMed Web of Science ®Google Scholar
• DinotaABilanciaDRomanoRManzioneLBiweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancerBreast Cancer Res Treat20058911315666190
   PubMed Web of Science ®Google Scholar
• BassoUFratinoLBrunelloAWhich benefit from adding gemcitabine to vinorelbine in elderly (> or =70 years) women with metastatic breast cancer? Early interruption of a phase II studyAnn Oncol2007181586317028243
   PubMed Web of Science ®Google Scholar
• AddeoRFaiolaVGuarrasiRLiposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or =65 years of ageCancer Chemother Pharmacol200862228529217922275
   PubMed Web of Science ®Google Scholar
• MlineritschBSchabel-MoserRAndelJMulticenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancerOnkologie2009321–2182419209014
   PubMedGoogle Scholar